NCIt definition : An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth
factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid
DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity.
The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization,
the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly
dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress
HER2. Linkage of antibody and drug through a nonreducible linker has been reported
to contribute to the improved efficacy and reduced toxicity of this ADC compared to
similar ADCs constructed with reducible linkers.;
UNII : SE2KH7T06F;
CAS number : 1018448-65-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1018448-65-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab-emtansine_position-preliminaire_final-27oct2014.pdf 2014 Canada drug information Metastatic Malignant Neoplasm in the Breast trastuzumab neoplasm, malignant HER2/Neu Positive HER2-Positive Breast Carcinoma breast neoplasms trastuzumab emtansine Trastuzumab Emtansine HER-2 positive breast cancer Ado-Trastuzumab Emtansine Breast Cancer Therapeutic Procedure breast cancer